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a  b  s  t  r  a  c  t
The  main  bacterium  associated  with  skin  infection  is Staphylococcus  aureus,  occurring  especially  in  infec-
tions  acquired  via  surgical  wounds,  commonly  leading  to lethal  hospital-acquired  infections,  emphasizing
the  importance  of  identifying  new  antimicrobial  compounds.  Among  them,  cyclotides  have  gained  inter-
est  due  to  their  high  stability  and  multifunctional  properties.  Here,  cycloviolacin  2 (CyO2)  and  kalata






tion  model.  Anti-staphylococcal  activities  of 50 mM  for  KB2  and  25  mM  for  CyO2  were  detected  with  no
cytotoxic  activities  against  RAW  264.7  monocytes.  In  the  in  vivo  assays,  both  cyclotides  reduced  bacterial
load  and  CyO2  demonstrated  an increase  in the  phagocytosis  index,  suggesting  that  the  CyO2  in vivo  anti-
staphylococcal  activity  may  be  associated  with  phagocytic  activity,  additionally  to  direct  anti-pathogenic
activity.
©  2014  Elsevier  Inc.  All  rights  reserved.ntroduction
The skin is the largest and the most exposed organ of the human
ody [26]. Although it is extremely effective in protecting host-
rganisms against external environmental threats, skin infections
re common and may  be caused by bacteria, fungi or viruses [26,28].
he main bacterium associated with skin infections is Staphy-
ococcus aureus [2,27]. The majority of infections can be simply
reated, but some are less tractable, especially those associated with
urgical wounds, which are the most common hospital-acquired
nfections and a major cause of morbidity and mortality [9,16].
hese infections are increasingly caused by pathogens that are
esistant to conventional treatments, which highlights the impor-
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196-9781/© 2014 Elsevier Inc. All rights reserved.tance of identifying new and more effective antimicrobial therapies
[1,32].
Antimicrobial peptides (AMPs) have emerged as a promising
new therapy with potential for the treatment of infectious dis-
eases [1,32]. Among AMPs, cyclotides have shown great promise
in a range of drug design applications. These head-to-tail cyclized
peptides, originally isolated from plants, incorporate six conserved
cysteine residues in their structure, which form three intercon-
nected disulﬁde bonds organized in a cyclic cystine knot (CCK)
motif. This motif makes cyclotides highly stable and has generated
interest in them as peptide-based scaffolds for designing medicines
[6,10,19]. The cyclotides can be divided into mainly two subfam-
ilies known as Möbius (Fig. 1A) and bracelet cyclotides (Fig. 1B);
the main characteristic that distinguishes one from the other is the
presence of a conserved cis-proline residue in loop 5 of the Möbius
subfamily, creating a twist in the circular backbone [4,8,10,29,40].
Here, the cyclotides cycloviolacin O2 (CyO2) and kalata B2
(KB2), respectively members of the bracelet and Möbius sub-
families (Fig. 1), were evaluated to characterize their cytotoxic
and anti-staphylococcal activities against S. aureus in an in vitro
microdilution assay and also in vivo using in a subcutaneous wound
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Ao  form six loops (1–6). CyO2 and KB2 belong to the bracelet and Möbius subfamily
n  Möbius cyclotides that gives a conceptual backbone twist resembling a Möbius s
nfection model. This study is the ﬁrst report deﬁning the efﬁcacy
f cyclotides in an in vivo infection model.
aterials and methods
eptides
The peptides used in this study, CyO2 and KB2, were
xtracted from the aerial parts of the plants Viola odorata
CyO2) and Oldenlandia afﬁnis (KB2) with a 1:1 solution of
ichloromethane/methanol for 12 h. The extract was  partitioned
ith water and the methanol/water fraction was rotary evaporate
o remove the methanol and lyophilized. The dried product was
esuspended in water and puriﬁed by RT-preparative HPLC using a
18 column. Peptide masses were analysed using an ES-TOF micro-
ass LCT mass spectrometer [7].
actericidal microdilution assays
Minimum inhibitory concentrations (MICs) of the cyclotides
gainst S. aureus ATCC 25923 were determined using a standard-
zed dilution method according to NCSLA guidelines [39]. A single
acterial colony was inoculated in Mueller-Hinton broth (MH)
Himedia, India) and incubated for 12 h at 37 ◦C. Overnight-cultured
. aureus was transferred to MH medium and cultured to expo-
ential phase (OD600 of ∼0.6). The culture was  centrifuged and
esuspended in sterile PBS and adjusted to a ﬁnal amount of
 × 105 colony-forming units (CFU) mL−1 by use of the equation
FU mL−1 = OD600 nm × 2.5 × 108 [35]. For MIC  determination, pep-
ides were applied at various concentrations (1–200 M)  from a
tock solution. Ten microliters of each concentration of peptide
olution was added to each corresponding well of a 96-well plate
Becton & Dickinson, USA) and 90 L of bacteria (1 × 105) in MH
edium was added. The polypropylene plates (TPP, Switzerland)
ere incubated at 37 ◦C for 24 h. MICs were determined as the low-
st tested concentration that leads to complete inhibition (100%)
ompared to the negative control group [33].
nimalsC57BL/6 mice weighting 18–22 g were used in this study, pro-
ided by the animal facility of the Catholic University of Brasilia.
ll animals were housed in separate cages under a constantectively. The two  subfamilies differ by the presence of conserved cis-Pro in loop 5
temperature (22 ◦C) and humidity, with a 12-h light/dark cycle and
access to food and water ad libitum throughout the study. The mice
were euthanized by CO2 or ether inhalation at the end of the exper-
iments. All procedures including care and handling of the animals
were approved by the Ethics Committee of the Catholic University
of Brasilia number 005/13.
Cell cytotoxicity assays
Murine monocytes RAW 264.7 cells (Rio de Janeiro Cell Bank)
were seeded in 96-well microtiter plates in a concentration
of 1.0 × 105 cells per well, in DMEM medium, supplemented
with various concentrations of the tested cyclotides (0.3–15 M).
After 24 and 48 h incubation, a 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide (MTT) cell viability assay was
performed. Brieﬂy, 60% of the medium was removed, and 10 L of
MTT  (5 mg  mL−1) (Sigma, USA) solution was  added to each well and
the plate was incubated for 4 h in 5% CO2 at 37 ◦C. The blue form-
azan product produced was dissolved by the addition of 100 L
of 100% DMSO (Mallinckrodt, Germany) per well. Plates were then
gently swirled for 5 min  at room temperature to dissolve the precip-
itate. The absorbance was monitored at 575 nm using a microplate
spectrophotometer (Bio-Tek, USA). Cytotoxicity was  determined as
a percentage of the maximum value after subtracting the back-
ground. The results were stated as the percentage of each sample
matched to the negative control (PBS buffer, pH 7.4) and cell cul-
ture was incubated in a lysis buffer (10 mM Tris, pH 7.4, 1 mM
ethylenediamine tetraacetic acid (EDTA), and 0.1% Triton X-100)
[39].
Induction of peritonitis and peritoneal cell collection
Peritonitis was induced as described by Leendertse et al. [23].
Mice were injected intraperitoneally with 200 L of 3% thioglycol-
late solution. Peritonitis was  induced 6 h after injection [23]. After
this period, mice were anesthetized by 10% ketamine (80 mg kg−1)
(Agener Union – Brazil) and xylazine (10 mg  kg−1) (Agener Union
– Brazil), euthanasiated, and a peritoneal lavage was performed
with 5 mL  of RPMI 1670 medium using an 18-gauge needle. After
collection of peritoneal lavage ﬂuid (PLF), cellular content was
immediately placed on ice. The numbers of total cells and neu-
trophils were counted using a microscope.
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hagocytosis assays
Phagocytosis assays were conducted using neutrophils (105
ells per well). Controls (untreated and treated with DMSO 2.5%
nd gentamicin 15 M)  and treatments with the previously deter-
ined cyclotide MIC  concentration were conducted in RPMI 1640
edium. The cells were infected with S. aureus at a multiplicity of
nfection (MOI) of 1:1 and incubated for 90 min. Following incuba-
ion, the cells were centrifuged, placed on slides and stained with
ast panoptic dye [34]. For neutrophil phagocytosis assay assess-
ents, at least 100 cells on each slide with or without phagocytosis
ere counted. Additionally, the number of phagocytosed particles
nd phagocytic index was calculated. In all experiments the phago-
ytosis conﬁrmatory counts were conducted by an independent
bserver. The phagocytic index (PI) was calculated using the
ormula: PI equals the percentage of cell phagocytosis multiplied
y the average number of particles phagocytosed by each cell.
urine surgical wound infection model
The murine surgical wound infection model was  performed as
escribed by McRipley and Whitney [24] with minor modiﬁcations.
ice (n = 5/group) were anesthetized, their dorsal surface shaved
nd the surgical area disinfected with 70% ethanol. A puncture was
erformed on the dorsal surface using 6-mm punch biopsy needles
Stiefel Laboratories, UK), and then 10 L of S. aureus ATCC 25923
uspension (2 × 109 mL−1; previously cultured as described in the
ection on bactericidal microdilution assays) was introduced into
he puncture wound, and the skin was closed with one silk suture
41]. Wounds were treated every 24 h with 20 L of a solution
ig. 2. Effect of cyclotides CyO2 (A) and KB2 (B) on viability of murine cell line RAW 264.7. 
alues represent the mean ± SD and data were analyzed by one-way ANOVA and Bonferro
acterial load of the wound from the C57BL/6 mice infected with S. aureus ATCC 25923 after
nd  treated with: DMSO 2.5%, Vetagls® (gentamicin 5 mg  kg−1, sulphanilamide 50 mg  kg−
B2  (0.75 mg kg−1, 1.5 mg  kg−1, 3.0 mg  kg−1). Values represent the mean ± SD and data w
 < 0.05; ** p < 0.01; *** p < 0.001 compared to the negative control. For the phagocytosis
ontrols: DMSO (2.5%), gentamicin (15 M)  or DMEM;  and treated with: (E) CyO2 (25 M
ne-way ANOVA and Bonferroni test: * p < 0.5; ** p < 0.01; *** p < 0.001 compared to untretides 63 (2015) 38–42
containing 0.75–3 mg  kg−1 of cyclotide. Vetaglos® (gentamicin
0.5%, sulfanilamide 5% and sulfadiazine 5%) ointment (Vetnil,
Brazil) was used as a positive control and PBS as negative control.
Mice were euthanized 7 days post-surgery; the wounded mus-
cle tissue was  excised, weighed, and homogenized in 1 mL  of PBS.
Serial homogenate dilutions were plated in triplicate on mannitol
salt agar (Himedia, India) and the results were stated as CFU g−1 of
tissue [18,35].
Statistical analysis
Data are presented as mean ± SD of all samples. Values of p < 0.05
were considered statistically signiﬁcant. GraphPad Prism software
v5.0 (GraphPad Software, USA) was used for all statistical analyses
[33].
Results
In vitro antibacterial activity
The activities of the cyclotides against S. aureus were evalu-
ated in vitro and MICs determined by microdilution tests (data not
shown). The MIC  for KB2 was 50 M and that for CyO2 was 25 M.
Effects of cyclotides in cell viability/metabolismCytotoxicity evaluation against RAW 264.7 cells for CyO2
(Fig. 2A) and KB2 (Fig. 2B) did not show signiﬁcant deleterious activ-
ities at the concentrations tested when compared with the control,
demonstrating that these peptides show no cytotoxicity to RAW
Cells were incubated for 24 and 48 h with CyO2 (27–438 nM), and KB2 (29–465 nM).
ni test: * p < 0.5; ** p < 0.01; *** p < 0.001 compared to untreated group. Recovery of
 6 days of treatment. The wounds were inoculated with 2×109 cells mL−1 of bacteria
1, sulfadiazine 50 mg  kg−1); (C) CyO2 (0.75 mg kg−1, 1.5 mg kg−1, 3.0 mg  kg−1); (D)
ere analysed by two-way ANOVA and Tukey’s test, with p < 0.05 as signiﬁcant: *
 assay, neutrophils extracted from healthy animals were incubated for 1.5 h with
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64.7 cells, at the evaluated concentrations (CyO2 ranging from
37.8 to 27.4 nM and KB2 ranging from 465.2 to 29.1 nM).
eriﬁcation of bacterial burdens recovered from wounds
Mice treated with 0.75 mg  kg−1 of CyO2 showed a slight reduc-
ion in bacterial load of 108 to ∼107. When treated with 1.5 and
.0 mg  kg−1, the bacterial load was reduced to ∼106 (Fig. 2C). In ani-
als treated with 6.0 mg  kg−1 of CyO2, a clear decrease in bacterial
oad of 108–105 was observed (data not shown). The infected mice
reated with KB2 showed a decrease in bacterial load of 108 to ∼106
n all tested concentrations (0.75, 1.5 and 3.0 mg  kg−1) (Fig. 2D).
valuation of phagocytosis
To evaluate possible indirect antibacterial activity through stim-
lation of the host, we measured the activity of cyclotides on
he phagocytic activity of neutrophils following S. aureus infec-
ion. Neutrophils treated with KB2 (Fig. 2E) showed no variation
n the phagocytic index compared with controls. However, CyO2
ncreased the phagocytic index by ∼545% (Fig. 2F), suggesting that
t has the capability of stimulating phagocytosis of S. aureus by
eutrophils.
iscussion
With the rapidly increasing prevalence of multidrug-resistant
acteria and the scarcity of new antibiotic research in the pharma-
eutical industry, the use of AMPs could be a promising alternative
o conventional antibiotic treatments. AMPs are multifunctional
ediators of the innate immune response with direct antimicrobial
nd immunomodulatory activities. Among AMPs, cyclotides are
otable for being small cyclic peptides with six conserved cysteine
esidues that form three interconnected disulﬁde bonds, thereby
iving them greater stability than linear AMPs [13,17,30]. Thus,
yclotides could potentially overcome some of the limitations of
eptides as drugs, such as sensitivity to proteolytic degradation
12,13,30].
In the present study the antibacterial activities of KB2 and CyO2
gainst S. aureus ATCC 25923 were evaluated. CyO2 had the best
nti-staphylococcal activity in vitro whereas KB2 had only slightly
ower potency. In the literature there are two  studies in which
yclotides were tested against S. aureus.  Tam et al. [36], reported
hat KB1, circulin A and B, and cyclopsychotride showed MICs
gainst S. aureus of 0.26 M,  0.19 M,  13.5 M and 39 M,  respec-
ively under low salt conditions but no activity under physiological
alt conditions [36]. Pranting et al. [31] evaluated CyO2, KB1, KB2,
aby A and D for activity against S. aureus,  but no deleterious activi-
ies against S. aureus were obtained using the radial diffusion assay,
erformed with 4 × 106 CFU in a culture medium based on sodium
hosphate buffer containing 0.03% (w/v) trypticase soy broth and
% agarose, with wells made using a 3 mm gel punch added 5 L of
ample, then incubated for 18–24 h, 37 ◦C. However, in microdi-
ution assays, these cyclotides inhibited S. aureus growth: CyO2
>50 M),  KB1 (>100 M),  KB2 (35 M),  Vaby A and D (>90 M)
31].
Given the conﬁrmation in our study of the anti-staphylococcal
ctivity of cyclotides KB2 and CyO2, we tested them for effects
n cell viability of murine RAW 264.7 monocytes and found
hat low doses did not cause any harmful effect. Otherwise any
valuation was performed at higher concentrations. Only KB2
howed slight cytotoxicity at higher doses (>15 M)  (data not
hown). Similar data were obtained by Grundemann et al. [11],
here O. afﬁnis extract and KB1 (1.8–14.0 M)  reduced peripheral
lood mononucleated cell (PBMC) proliferation. That study showedtides 63 (2015) 38–42 41
that at concentrations of 1.8–14 M a dose-dependent correlation
decrease in cell proliferation was  observed.
Since in vitro antibacterial activity, but no mammalian cytotox-
icity, was observed in the two cyclotides tested here, the next step
was to evaluate their in vivo anti-staphylococcal activity using a
surgical S. aureus wound infection model. To our knowledge, there
has been no previous report of cyclotide antimicrobial activity in an
animal infection model. The cyclotides showed similar responses,
and both decreased bacterial load. Interestingly, a progressive dose
response was  not observed, probably due to the low concentrations
tested. A similar phenomenon was  observed with the antimicrobial
peptide PXL150, which all tested concentrations showed activity
toward S. aureus [25].
A number of other studies have reported in vivo antibacterial
activity of AMPs using the surgical wound model used here. For
example, coprisin (5 mg  kg−1), in addition to reducing the bacte-
rial load, accelerated the wound healing process [21]. In another
study, PEP35 exhibited poor antimicrobial activity in vitro, with
MIC50 values for various clinical strains of S. aureus isolates of
approximately 500 g mL−1. Nevertheless, this peptide showed
immunomodulatory activity, and when tested in vivo in the sur-
gical wound model, reduced the bacterial load to approximately
102 CFU g−1 tissue, probably recruiting neutrophils to the infection
site [22]. In another study, epinecidin peptide-1 (EPI-1) was  evalu-
ated against MRSA (106 CFU), with treatments placed on the wound
5 min  after infection, which was covered after 30 min to prevent
interference by the animal [15]. Groups treated with EPI-1 showed
an improved survival rate with a decrease in bacterial load of 106 to
∼20 to CFU g−1 tissue [15]. In a study using the same methodology,
the pardaxin peptide (GE33) led to complete bacterial clearance in a
surgical wound model infected with 106 CFU of S. aureus.  The activ-
ities of the cyclotides tested here are comparable to those reported
in these previous studies.
To observe whether the in vivo effects of the cyclotides could
be related simply to direct antibacterial activity or also to addi-
tional indirect host activity, a phagocytosis assay was performed
to assess the stimulation of neutrophils to increase S. aureus
phagocytosis. KB2 showed no change compared with the controls,
suggesting that the mechanism of action is based predominantly
on bactericidal activity. By contrast, CyO2 showed an increase
in phagocytic index of approximately 550%, suggesting that its
in vivo activity against S. aureus might be associated with both
bactericidal and phagocytic induction in the host animal. It is
interesting that this dual strategy is not seen with KB2. Other
antimicrobial peptides have been reported to induce phagocytic
activity, such as LL-37, which was  able to enhance phagocytosis
of opsonized Gram-negative and Gram-positive bacteria, besides
improving the phagocytosis of non-opsonized Escherichia coli in
human macrophages [38]. Another peptide that leads to improved
phagocytic activity in macrophages is hLF1-11, which was shown
to improve the phagocytosis of not only S. aureus,  but also Candida
albicans [37].
In conclusion, CyO2 and KB2 might represent a starting point
for a novel therapeutic approach for the local treatment of infec-
tions. Cyclotides can be produced recombinantly [3] or chemically
[5], which opens new frontiers for the production of cyclotide-
based medicines. The exceptional stability and cell penetrating
properties of cyclotides make them possible scaffolds for the
grafting of known active peptides for the engineering of peptide-
based drugs [20]. Such an approach might be used to enhance
the natural antimicrobial activity of the cyclotide framework,
which appears to be driven mainly by membrane binding and
disruption [14]. However, more studies are needed to evalu-
ate the applicability of these cyclic AMPs as well as to shed
additional light on their in vivo antibactericidal mechanism of
action.
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